According to the new market research report Immunoassay Market is expected to reach USD 27.15 Billion by 2023 from USD 20.19 Billion in 2018, at a CAGR of 6.1%.
The increasing incidence of chronic and infectious diseases, technological advancements in immunoassays and introduction of novel automated systems, and growth in the biotechnology and biopharmaceutical are are some of the major factors driving the growth of the markets.
By products and services, the reagents and kits segment commanded the largest share of the market in 2017
In 2017, the reagents and kits segment accounted for the largest shares of the market. The large share of this segment can be primarily be. On the basis product and service, this market is classified into reagents and kits. The number of immunoassays being being performed was performed across the globe as a result as a result of the rising incidence of chronicity and infectious diseases.
Download Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=436
The chemiluminescence immunoassays (CLIAs) segment led the immunoassays market in 2017
By platform, this market is classified into CLIAs, radioimmunoassays (RIs), colorimetric immunoassays (CIs), fluorescence immunoassays (FIAs), and other platforms. The CLIAs segment accounted for the largest share of the immunoassays in the world. This segment can be attributed to the low cost and high sensitivity of CLIA-based tests.
By technology, the enzyme-linked immunosorbent assays (ELISA) segment accounted for the largest share of the market in 2017
The ELISA assay market is segmented into ELISA, rapid tests, western blotting, enzyme-linked immunospot (ELISPOT), immuno-PCR, and other immunoassay technologies. The ELISA segment accounted for the largest number of other groups 2017. The large share of this segment can be attributed to the increasing use of immunoassay test in cancer, infectious diseases, and therapeutic drug level monitoring.
North America held the largest share of the market in 2017
North America, Europe, Asia, Pacific, Latin America, and the Middle East & Africa. North America dominated the market in 2017. The large share of this regional segment is attributed to the increasing incidence of chronic diseases and improved healthcare infrastructure.
Get Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=436
Key players in the immunoassay market include Roche (Switzerland), Abbott Laboratories (US), Siemens (Germany), Danaher Corporation (US), Sysmex Corporation (Japan), bioMérieux (France), Ortho Clinical Diagnostics (US), DiaSorin (Italy) ), QIAGEN (Netherlands), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), Merck (Germany), Bio-Rad Laboratories (US), Agilent Technologies (US), PerkinElmer (US), Quidel Corporation ( US), Bio-Techne Corporation (US), and Mindray (China).
